Evercore analyst Gavin Clark-Gartner maintains $argenx SE (ARGX.US)$ with a buy rating, and maintains the target price at $706.
According to TipRanks data, the analyst has a success rate of 46.3% and a total average return of 22.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $argenx SE (ARGX.US)$'s main analysts recently are as follows:
The continuation of Phase 3 across all three myositis subtypes is seen as a positive factor that could enhance future pipeline value, though it may not significantly impact stock movement immediately. The analysis included a 70% probability of success for myositis, with adjustments anticipated upon the release of full data at an upcoming medical conference.
Argenx's announcement about achieving clinical proof-of-concept in myositis with subQ efgart showing statistically significant improvement across all three evaluated myositis subtypes in Phase 2 has been positively noted. This development is seen as enhancing Argenx's position in the autoimmune sector, and detailed results are anticipated at a future medical conference.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析師Gavin Clark-Gartner維持$argenx SE (ARGX.US)$買入評級，維持目標價706美元。
根據TipRanks數據顯示，該分析師近一年總勝率為46.3%，總平均回報率為22.2%。
此外，綜合報道，$argenx SE (ARGX.US)$近期主要分析師觀點如下：
在所有三種肌炎亞型中繼續進行第3階段被視爲一個積極因素，可能增強未來的管道價值，儘管可能不會立即對股票走勢產生重大影響。分析包括肌炎成功概率爲70％，預計隨着即將舉行的醫療會議發佈完整數據而進行調整。
Argenx宣佈在第2階段中通過亞Q efgart顯示了在所有三種評估的肌炎亞型中實現了臨床概念的臨床證據，這一進展被積極關注。這一發展被視爲增強了Argenx在自身免疫板塊中的地位，並期待在未來的醫療會議上公佈詳細結果。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
